Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD

Holtmann, Gerald, Bigard, Marc-Andre, Malfertheiner, Peter and Pounder, Roy (2011) Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD. International Journal of Clinical Pharmacy, 33 3: 493-500. doi:10.1007/s11096-011-9489-y

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
Holtmann_Gerald_authoraffil_staffdata.pdf Holtmann_Gerald_authoraffil_staffdata.pdf application/pdf 245.74KB 0

Author Holtmann, Gerald
Bigard, Marc-Andre
Malfertheiner, Peter
Pounder, Roy
Title Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD
Journal name International Journal of Clinical Pharmacy   Check publisher's open access policy
ISSN 2210-7703
Publication date 2011-06-01
Sub-type Article (original research)
DOI 10.1007/s11096-011-9489-y
Open Access Status
Volume 33
Issue 3
Start page 493
End page 500
Total pages 8
Place of publication Dordrecht, Netherlands
Publisher Springer
Language eng
Formatted abstract
Objective: The aim of this paper was to develop a guideline on the over-the-counter management of gastroesophageal reflux disease with proton pump inhibitors (i.e. omeprazole). Setting A meeting of internationally renowned gastroenterologists in January 2009, in Berlin, Germany.

Methods: An expert panel group of gastroenterologists convened to develop a consensus-based algorithm for pharmacists for over-the-counter (OTC) treatment with proton pump inhibitors (PPIs). Key considerations were the short-term safety and efficacy of PPIs, and the extent of the risk to the sufferer, owing to the treatment not being controlled by a physician. Main outcome measures A consensus-based treatment algorithm for the OTC management of gastroesophageal reflux disease and evidence-based guidance on the use of OTC PPIs.

Results: As defined by the treatment algorithm, the pharmacist should first confirm the diagnosis based on the presence of typical symptoms and secondly, as a result, rule out general practitioner referral. The third step focuses on the nature, severity and frequency of the symptoms—the patients who might have the highest benefit from a short course (14 days) of OTC PPIs are those with less than three episodes of heartburn and/or acid regurgitation per week. Patients who have three or more episodes per week can use the OTC PPIs but should also be encouraged to visit a physician, and those who already have a diagnostic work-up can use proton pump inhibitors as rescue treatment if they are known responders. Guidance for pharmacists, in the form of questions and answers, summarises the current published clinical experience with PPIs in terms of their efficacy and safety, and optimal treatment schedule.

Conclusions: Gastroesophageal reflux disease imposes a considerable burden on sufferers. Owing to their accepted efficacy and safety, PPIs are becoming popular as OTC options for the treatment of gastroesophageal reflux disease symptoms such as heartburn and acid regurgitation. Effective self-management of gastroesophageal reflux disease with OTC PPIs, e.g. omeprazole, could lead to lasting freedom from symptoms and improved quality of life for sufferers.
Keyword Gastroesophageal reflux disease
OTC drugs
Proton pump inhibitors
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2012 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 15 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 10 Oct 2011, 21:40:20 EST by Matthew Lamb on behalf of School of Medicine